SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann, Hannah Kleine‐Weber, Simon Schroeder et al. · Cell · 2020 · 21.1K citations · Full text

Medicine, Viral Pathogenesis, Immunology +8

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Renhong Yan, Yuanyuan Zhang, Yaning Li et al. · Science · 2020 · 5.5K citations · Full text

Presumed Asymptomatic Carrier Transmission of COVID-19

Yan Bai, Yao Ling-sheng, Tao Wei et al. · JAMA · 2020 · 4.8K citations · Full text

Virus Epidemiology, Family Members, Emerging Infectious Diseases +12

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Michael Letko, Andrea Marzi, Vincent J. Munster · Nature Microbiology · 2020 · 3.4K citations · Full text

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Xiuyuan Ou, Yan Liu, Xiaobo Lei et al. · Nature Communications · 2020 · 3.4K citations · Full text